Showing 2821-2830 of 5646 results for "".
- Ocular Therapeutix Announces Completion of Debt Refinancinghttps://modernod.com/news/ocular-therapeutix-announces-completion-of-debt-refinancing/2476236/Ocular Therapeutix announced that it has closed a refinancing of its existing debt by entering into a new $25 million term loan with MidCap Financial and Silicon Valley Bank. The 5-year term loan facility allows for an expansion of the company’s prior $18 million credit facility to $25 mil
- Chugai’s Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disordershttps://modernod.com/news/chugais-satralizumab-receives-fda-breakthrough-therapy-designation-for-neuromyelitis-optica-and-neuromyelitis-optica-spectrum-disorders/2476249/Japan-based Chugai Pharmaceutical announced that the FDA has granted breakthrough therapy designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NM
- Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese Markethttps://modernod.com/news/nicox-and-ocumension-therapeutics-sign-exclusive-license-agreement-to-develop-and-commercialize-ncx-470-in-the-chinese-market/2479610/Nicox and Ocumension Therapeutics announced they have entered into an exclusive license agreement for the development and commercialization of Nicox’s product candidate, NCX 470, targeting patients with glaucoma or ocular hypertension
- University of Dayton Researcher Named on Second Patent for Device to Provide Better Relief for Glaucoma Patientshttps://modernod.com/news/university-of-dayton-researcher-named-on-second-patent-for-device-to-provide-better-relief-for-glaucoma-patients/2479616/Khalid Lafdi, University of Dayton Wright Brothers Endowed Chair in Nanomaterials, was named on a second patent for a medical drainage device mainly for glaucoma patients that also could be used for drainage in the ears, brain, or chest or to provide access to larger veins or arteries, according
- Ophthalmic Investment Funds Led by Retinal Gene Therapy Developershttps://modernod.com/news/ophthalmic-investment-funds-led-by-retinal-gene-therapy-developers/2476147/Ophthalmology remains one of the most active areas of medical technology investment, attracting monies from venture capitalists, public markets, large ophthalmic companies, and private equity. Market Scope just published its 2017/2018 Ophthalmic Deals Book, analyzing recent ophthalmic fund
- Akorn CEO Steps Down After Loss of $4.3 Billion Fresenius Dealhttps://modernod.com/news/akorn-ceo-steps-down-after-loss-of-4-3-billion-fresenius-deal/2476150/Akorn’s CEO stepped down after the Delaware Supreme Court ruled that a rapid downturn in its business was grounds for Fresenius SE to walk away from a $4.3 billion buyout of the generic drugmaker, according to a Bloomberg News
- Study: Ocular Technology Provides Early Detection of Alzheimer’s Diseasehttps://modernod.com/news/study-ocular-technology-provides-early-detection-of-alzheimers-disease/2479626/A recent study from JAMA Ophthalmology finds that a specific type of noninvasive eye testing procedure may help assess risk for Alzheimer’s disease. One in 10 Americans over the age 65 has Alzheimer’s, while one-third over the age of 85 have the disease. Fortunately, res
- Alcon’s Phaco Development (PD) Program Celebrates 10 Yearshttps://modernod.com/news/alcons-phaco-development-pd-program-celebrates-10-years/2476164/The Phaco Development (PD) program, an initiative between Alcon and specialist training institutes that builds cataract surgical capabilities across Asia and Russia, is celebrating its 10th anniversary this year. Over th
- Bausch + Lomb Announces Exclusive Agreement with Modulight to Develop New Photodynamic Laserhttps://modernod.com/news/bausch-lomb-announces-exclusive-agreement-with-modulight-to-develop-new-photodynamic-laser/2476166/Bausch + Lomb and Modulight, a designer and manufacturer of lasers and optics for personalized medicine, announced the companies have entered into an exclusive agreement to collaborate and develop a new laser specifically designed for use with Bausch + Lomb’s Visudyne (verteporfin for injection)
- Ocular Therapeutix Announces FDA Approval of Dextenza for the Treatment of Ocular Pain Following Ophthalmic Surgeryhttps://modernod.com/news/ocular-therapeutix-announces-fda-approval-of-dextenza-for-the-treatment-of-ocular-pain-following-ophthalmic-surgery/2476171/Ocular Therapeutix announced that the FDA has approved Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. Dextenza is the first FDA-approved intracanalicular insert delivering dexamethasone to treat post-